Addex Therapeutics Ltd ADR(ADXN-Q)NASDAQ
Today's Change
Real-Time Last Update
Pre Market Change
Pre Market Last Update
Volume
Latest News
Addex Completes $4.2 Million Equity Financing
Globe Newswire - Tue Jul 26, 2022
Globe Newswire
Tue Jul 26, 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
Addex Shareholders Approve All Resolutions at Annual General Meeting
Globe Newswire - Tue May 10, 2022
Globe Newswire
Tue May 10, 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company...
Addex Reports Q1 2022 Financial Results
Globe Newswire - Thu May 5, 2022
Globe Newswire
Thu May 5, 2022
CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022Phase...
Addex Convenes Annual General Meeting 2022
Globe Newswire - Thu Mar 31, 2022
Globe Newswire
Thu Mar 31, 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 31, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences
Globe Newswire - Thu Mar 24, 2022
Globe Newswire
Thu Mar 24, 2022
Geneva, Switzerland, March 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Reports Full Year 2021 Financial Results and Provides Corporate Update
Globe Newswire - Thu Mar 10, 2022
Globe Newswire
Thu Mar 10, 2022
CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2...
Addex to Present at the Virtual Sachs Associates 3rd Annual European HealthTech and 15th Annual European Life Sciences CEO Forums
Globe Newswire - Thu Feb 24, 2022
Globe Newswire
Thu Feb 24, 2022
Geneva, Switzerland, February 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex to Present at the Swiss Equities Baader Virtual Conference
Globe Newswire - Tue Jan 11, 2022
Globe Newswire
Tue Jan 11, 2022
Geneva, Switzerland, January 11, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Globe Newswire - Thu Jan 6, 2022
Globe Newswire
Thu Jan 6, 2022
Geneva, Switzerland, January 6 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Raises $10.0 Million in Equity Financing
Globe Newswire - Fri Dec 17, 2021
Globe Newswire
Fri Dec 17, 2021
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
Addex Provides Year End Pipeline Development Update
Globe Newswire - Wed Dec 15, 2021
Globe Newswire
Wed Dec 15, 2021
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, 15 December 2021 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
Addex Reports Q3 2021 Financial Results and Provides Corporate Update
Globe Newswire - Thu Nov 4, 2021
Globe Newswire
Thu Nov 4, 2021
CHF15.5M ($16.6M) of cash and cash equivalents at September 30, 2021Cash used in Q3 2021 of CHF2.6MDipraglurant Phase 2 blepharospasm clinical trial...
Addex to Present at the Cantor Global Healthcare 2021 Conference
Globe NewsWire - Wed Sep 29, 2021
Globe NewsWire
Wed Sep 29, 2021
Geneva, Switzerland, September 29 , 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at...
CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A
Globe NewsWire - Wed Sep 22, 2021
Globe NewsWire
Wed Sep 22, 2021
Ad Hoc Announcement Pursuant to Art. 53 LR
Addex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Globe NewsWire - Wed Sep 8, 2021
Globe NewsWire
Wed Sep 8, 2021
Geneva, Switzerland , September 8 , 202 1 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will...
Addex to Present at the Swiss Biotech Day
Globe NewsWire - Thu Sep 2, 2021
Globe NewsWire
Thu Sep 2, 2021
Geneva, Switzerland , September 2 , 202 1 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will...
Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update
Globe NewsWire - Thu Aug 5, 2021
Globe NewsWire
Thu Aug 5, 2021
Ge neva, Switzerland, August 5 , 20 2 1 - Ad Hoc Announcement Pursuant to Art. 53 LR
Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021
Globe NewsWire - Mon Aug 2, 2021
Globe NewsWire
Mon Aug 2, 2021
Geneva, Switzerland, August 2 , 20 21 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it...
Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science
Globe NewsWire - Mon Aug 2, 2021
Globe NewsWire
Mon Aug 2, 2021
Geneva, Switzerland , August 2 , 202 1 ( GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR
Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding
Globe NewsWire - Thu Jul 29, 2021
Globe NewsWire
Thu Jul 29, 2021
IND enabling studies with Indivior collaboration drug candidate and separate Addex program scheduled for 2022
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
AccessWire - Thu Jul 8, 2021
AccessWire
Thu Jul 8, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over...
Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021
Globe NewsWire - Wed Jul 7, 2021
Globe NewsWire
Wed Jul 7, 2021
Geneva, Switzerland , July 7 , 202 1 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim...
Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators
Globe NewsWire - Thu Jul 1, 2021
Globe NewsWire
Thu Jul 1, 2021
Ad Hoc Announcement Pursuant to Art. 53 LR
Addex Establishes At-The-Market ADS Equity Sale Program
Globe NewsWire - Wed Jun 30, 2021
Globe NewsWire
Wed Jun 30, 2021
Geneva, Switzerland, June 30 , 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the company has entered into a sales...
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
AccessWire - Wed Jun 23, 2021
AccessWire
Wed Jun 23, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private...